Parmax Pharma

Market Cap: Micro Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE240T01014
NSEID:
BSEID: 540359

INR

39.00

-5.7 (-12.75%)

BSENSE

Apr 11, 12:52 PM

BSE+NSE Vol: 18

{
  "main_header": {
    "sid": 1002724,
    "name": "Parmax Pharma",
    "stock_name": "Parmax Pharma",
    "full_name": "Parmax Pharma Ltd",
    "name_url": "stocks-analysis/parmax-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "39.00",
    "chg": -5.7,
    "chgp": "-12.75%",
    "dir": -1,
    "prev_price": "44.70",
    "mcapval": "14.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540359,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE240T01014",
    "curr_date": "Apr 11, 12:52 PM",
    "curr_time": "01:14 AM",
    "bse_nse_vol": "18 ",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/parmax-pharma-1002724-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Parmax Pharma Experiences Strong Buying Momentum Amid Market Fluctuations",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parmax-pharma-ltd-rises-2-00-today-accumulates-4-04-gains-over-two-days-1638644",
        "imagepath": "",
        "date": "2025-03-28 09:35:32",
        "description": "Parmax Pharma Ltd is currently witnessing strong buying activity, with the stock gaining 2.00% today, significantly outperforming the Sensex, which has declined by 0.20%. This marks the second consecutive day of gains for Parmax Pharma, accumulating a total return of 4.04% over this period. \n\nIn terms of performance metrics, Parmax Pharma has shown a robust annual increase of 48.31%, while the Sensex has only risen by 5.16% in the same timeframe. However, the stock has faced challenges over the past month, with a decline of 1.05%, contrasting with the Sensex's gain of 5.81%. \n\nToday's trading session opened with a gap up, indicating positive market sentiment. The stock's intraday performance has remained strong, supported by moving averages that are higher than the 5-day, 20-day, 50-day, and 200-day averages, although it remains below the 100-day moving average. \n\nFactors contributing to the current buying ..."
      },
      {
        "title": "Parmax Pharma Ltd Experiences Increased Buying Activity Amid Recent Price Declines",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parmax-pharma-ltd-achieves-33-41-yearly-gain-despite-recent-price-declines-and-market-trends-1546152",
        "imagepath": "",
        "date": "2025-03-21 10:20:16",
        "description": "Parmax Pharma Ltd is currently witnessing significant buying activity, despite its recent performance trends. Over the past week, the stock has declined by 4.14%, contrasting sharply with the Sensex, which has gained 3.67%. This trend continues over the month, with Parmax Pharma down 6.95% compared to the Sensex's modest rise of 1.63%. \n\nIn the short term, the stock has struggled, showing a 16.47% decrease over the last three months, while the Sensex has only dipped by 1.92%. However, Parmax Pharma has shown resilience over the past year, with a notable increase of 33.41%, significantly outperforming the Sensex's 5.37% gain.\n\nToday's trading session opened with a gap up, indicating initial buyer enthusiasm, but the stock has underperformed its sector by 0.86%. It is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend in the short to medium term..."
      },
      {
        "title": "Parmax Pharma Faces Increased Selling Pressure Amid Ongoing Price Declines",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parmax-pharma-ltd-faces-selling-pressure-with-1-99-decline-amidst-significant-losses-1406171",
        "imagepath": "",
        "date": "2025-03-17 15:25:12",
        "description": "Parmax Pharma Ltd is currently facing significant selling pressure, with today's trading session showing a complete lack of buyers. The stock has recorded a loss of 1.99% today, contrasting sharply with the Sensex, which has gained 0.44%. This marks a continuation of a downward trend, as Parmax Pharma has experienced consecutive days of losses, with a weekly decline of 2.01% compared to the Sensex's modest increase of 0.05%.\n\nOver the past month, Parmax Pharma's performance has been relatively strong, up 7.57%, while the Sensex has dipped by 2.43%. However, the three-month outlook reveals a decline of 11.22% for Parmax Pharma, underperforming the Sensex, which fell by 8.10%. Year-to-date, the stock is down 7.55%, slightly worse than the Sensex's decline of 5.10%. \n\nThe stock's price summary indicates it is currently underperforming its sector by 3.24%. While it remains above the 200-day moving average, it i..."
      },
      {
        "title": "Parmax Pharma Ltd Experiences Notable Buying Activity Amid Sector Resilience",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parmax-pharma-ltd-surges-61-16-annually-outperforming-sensex-amid-recent-price-gains-1348478",
        "imagepath": "",
        "date": "2025-03-13 15:25:11",
        "description": "Parmax Pharma Ltd is currently witnessing significant buying activity, marking a notable trend in the microcap pharmaceuticals and drugs sector. Over the past week, the stock has gained 2.63%, contrasting sharply with the Sensex, which has declined by 0.65%. This positive momentum continues over the month, with Parmax Pharma up 1.80% while the Sensex has dropped 3.00%.\n\nDespite a challenging three-month period where Parmax Pharma fell by 11.19%, it has shown remarkable resilience over the past year, boasting a 61.16% increase compared to the Sensex's modest 1.50% rise. Year-to-date, the stock is down 5.67%, slightly underperforming the Sensex's decline of 5.48%. However, over a five-year horizon, Parmax Pharma has outperformed the Sensex with a substantial 160.88% increase.\n\nToday's trading session opened with a gap up, and the stock has consistently outperformed its sector by 0.32%. While it remains above ..."
      },
      {
        "title": "Parmax Pharma Experiences Strong Buying Activity Amid Notable Price Gains",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parmax-pharma-ltd-gains-49-21-over-past-year-reaches-intraday-high-amid-strong-buying-activity-1377287",
        "imagepath": "",
        "date": "2025-03-12 09:50:13",
        "description": "Parmax Pharma Ltd is currently witnessing significant buying activity, reflecting a strong interest in the stock. Over the past week, Parmax Pharma has gained 0.60%, outperforming the Sensex, which recorded a modest increase of 0.51%. In the past month, the stock has shown a notable rise of 3.09%, while the Sensex declined by 2.71%. \n\nDespite a challenging three-month period where Parmax Pharma fell by 7.22%, it has demonstrated resilience over the past year with a remarkable gain of 49.21%, compared to the Sensex's slight increase of 0.60%. Year-to-date, the stock is down 5.65%, slightly underperforming the Sensex's decline of 5.16%. Over a five-year horizon, Parmax Pharma has surged by 160.94%, significantly outpacing the Sensex's 126.09% growth.\n\nToday's trading session opened with a gap up, indicating positive market sentiment. The stock is currently positioned above its 5-day and 200-day moving average..."
      },
      {
        "title": "Parmax Pharma Faces Intense Selling Pressure Amid Significant Price Declines",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parmax-pharma-ltd-faces-significant-selling-pressure-stock-declines-9-98-amid-seller-dominance-1189763",
        "imagepath": "",
        "date": "2025-03-04 10:53:30",
        "description": "Parmax Pharma Ltd is currently facing significant selling pressure, with the stock showing only sellers today. The company has experienced consecutive days of losses, with a notable decline of 9.98% in just one day, compared to a minimal drop of 0.20% in the Sensex. Over the past week, Parmax Pharma's performance has worsened by 10.63%, while the Sensex fell by 2.23%. \n\nIn the last month, the stock has declined by 11.66%, significantly underperforming the Sensex, which decreased by 7.18%. The three-month performance reveals a stark drop of 21.97% for Parmax Pharma, against the Sensex's 9.90% decline. Year-to-date, the stock is down 13.15%, while the Sensex has fallen by 6.66%. \n\nDespite a strong one-year performance of 21.46%, Parmax Pharma's three-year performance shows a decline of 14.60%, contrasting sharply with the Sensex's growth of 34.24%. The stock's erratic trading pattern, with no trades on one da..."
      },
      {
        "title": "Parmax Pharma Faces Intensified Selling Pressure Amid Ongoing Price Declines",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parmax-pharma-ltd-faces-significant-selling-pressure-with-11-06-loss-over-three-months-1171956",
        "imagepath": "",
        "date": "2025-03-03 10:25:03",
        "description": "Parmax Pharma Ltd is currently facing significant selling pressure, with today's trading session showing only sellers in the market. This trend marks a continuation of consecutive days of losses for the microcap pharmaceutical company. Over the past week, Parmax Pharma has declined by 2.04%, slightly outperforming the Sensex, which fell by 2.13%. However, the stock's performance over the past month shows a loss of 5.55%, closely trailing the Sensex's decline of 5.60%.\n\nIn the last three months, Parmax Pharma has experienced a more pronounced drop of 11.06%, compared to the Sensex's 9.87% decline. Despite a strong yearly performance of 31.39% against the Sensex's -1.27%, the stock has struggled in the year-to-date, down 3.53% versus the Sensex's 6.75% loss. Over three years, Parmax Pharma has underperformed with a decline of 5.87%, while the Sensex has surged by 32.24%. \n\nToday's trading activity indicates e..."
      },
      {
        "title": "Parmax Pharma Reports Strong Sales Growth Amid Market Reevaluation in February 2025",
        "link": "https://www.marketsmojo.com/news/result-analysis/parmax-pharma-reports-188-15-year-on-year-growth-in-net-sales-for-dec24-1040721",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/ParmaxPharma_quaterlyResult_451558.png",
        "date": "2025-02-17 11:16:33",
        "description": "Parmax Pharma announced its financial results for the quarter ending December 2024, revealing net sales of Rs 15.56 crore, marking a year-on-year growth of 188.15%. This performance underscores the company's operational momentum, while a recent adjustment in its market score indicates a reassessment of its overall standing in the competitive pharmaceuticals sector."
      }
    ],
    "total": 27,
    "sid": "1002724",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/parmax-pharma-1002724"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "24-Mar-2025",
      "details": "Pursuant to SEBI (PIT) Regulations 2015 trading window for dealing in securities of the company for designated persons will remain closed from 1st April 2025 till 48 hours after declaration of financial results for the quarter ending on 31st March 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
      "datetime": "14-Feb-2025",
      "details": "Pursuant to the provisions of Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the Board of Directors of the Company at its meeting held today i.e. November 14 2024 inter alia has considered and approved: 1. The Unaudited Financial Results of the Company for the quarter and half year ended on September 30 2024. The same has also been reviewed by the Audit Committee in its meeting held today. 2. B A Shah S R Mehta & Co. Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Financial Results for the quarter and half year ended on September 30 2024 and the Board has also taken on record their Limited Review Report on the said Results.",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For The Quarter Ended On 31St December 2024",
      "datetime": "14-Feb-2025",
      "details": "Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations 2015 the board of directors of the company at its meeting held today i.e. 14th February 2025 inter alia considered and approved Unaudited financial results of the company for the quarter ended on 31 st December 2024 along with Limited Review report provided by statutory auditors of the company.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Parmax Pharma Experiences Strong Buying Momentum Amid Market Fluctuations

2025-03-28 09:35:32

Parmax Pharma Ltd is currently witnessing strong buying activity, with the stock gaining 2.00% today, significantly outperforming the Sensex, which has declined by 0.20%. This marks the second consecutive day of gains for Parmax Pharma, accumulating a total return of 4.04% over this period. In terms of performance metrics, Parmax Pharma has shown a robust annual increase of 48.31%, while the Sensex has only risen by 5.16% in the same timeframe. However, the stock has faced challenges over the past month, with a decline of 1.05%, contrasting with the Sensex's gain of 5.81%. Today's trading session opened with a gap up, indicating positive market sentiment. The stock's intraday performance has remained strong, supported by moving averages that are higher than the 5-day, 20-day, 50-day, and 200-day averages, although it remains below the 100-day moving average. Factors contributing to the current buying ...

Parmax Pharma Ltd Experiences Increased Buying Activity Amid Recent Price Declines

2025-03-21 10:20:16

Parmax Pharma Ltd is currently witnessing significant buying activity, despite its recent performance trends. Over the past week, the stock has declined by 4.14%, contrasting sharply with the Sensex, which has gained 3.67%. This trend continues over the month, with Parmax Pharma down 6.95% compared to the Sensex's modest rise of 1.63%. In the short term, the stock has struggled, showing a 16.47% decrease over the last three months, while the Sensex has only dipped by 1.92%. However, Parmax Pharma has shown resilience over the past year, with a notable increase of 33.41%, significantly outperforming the Sensex's 5.37% gain. Today's trading session opened with a gap up, indicating initial buyer enthusiasm, but the stock has underperformed its sector by 0.86%. It is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend in the short to medium term...

Parmax Pharma Faces Increased Selling Pressure Amid Ongoing Price Declines

2025-03-17 15:25:12

Parmax Pharma Ltd is currently facing significant selling pressure, with today's trading session showing a complete lack of buyers. The stock has recorded a loss of 1.99% today, contrasting sharply with the Sensex, which has gained 0.44%. This marks a continuation of a downward trend, as Parmax Pharma has experienced consecutive days of losses, with a weekly decline of 2.01% compared to the Sensex's modest increase of 0.05%. Over the past month, Parmax Pharma's performance has been relatively strong, up 7.57%, while the Sensex has dipped by 2.43%. However, the three-month outlook reveals a decline of 11.22% for Parmax Pharma, underperforming the Sensex, which fell by 8.10%. Year-to-date, the stock is down 7.55%, slightly worse than the Sensex's decline of 5.10%. The stock's price summary indicates it is currently underperforming its sector by 3.24%. While it remains above the 200-day moving average, it i...

Parmax Pharma Ltd Experiences Notable Buying Activity Amid Sector Resilience

2025-03-13 15:25:11

Parmax Pharma Ltd is currently witnessing significant buying activity, marking a notable trend in the microcap pharmaceuticals and drugs sector. Over the past week, the stock has gained 2.63%, contrasting sharply with the Sensex, which has declined by 0.65%. This positive momentum continues over the month, with Parmax Pharma up 1.80% while the Sensex has dropped 3.00%. Despite a challenging three-month period where Parmax Pharma fell by 11.19%, it has shown remarkable resilience over the past year, boasting a 61.16% increase compared to the Sensex's modest 1.50% rise. Year-to-date, the stock is down 5.67%, slightly underperforming the Sensex's decline of 5.48%. However, over a five-year horizon, Parmax Pharma has outperformed the Sensex with a substantial 160.88% increase. Today's trading session opened with a gap up, and the stock has consistently outperformed its sector by 0.32%. While it remains above ...

Parmax Pharma Experiences Strong Buying Activity Amid Notable Price Gains

2025-03-12 09:50:13

Parmax Pharma Ltd is currently witnessing significant buying activity, reflecting a strong interest in the stock. Over the past week, Parmax Pharma has gained 0.60%, outperforming the Sensex, which recorded a modest increase of 0.51%. In the past month, the stock has shown a notable rise of 3.09%, while the Sensex declined by 2.71%. Despite a challenging three-month period where Parmax Pharma fell by 7.22%, it has demonstrated resilience over the past year with a remarkable gain of 49.21%, compared to the Sensex's slight increase of 0.60%. Year-to-date, the stock is down 5.65%, slightly underperforming the Sensex's decline of 5.16%. Over a five-year horizon, Parmax Pharma has surged by 160.94%, significantly outpacing the Sensex's 126.09% growth. Today's trading session opened with a gap up, indicating positive market sentiment. The stock is currently positioned above its 5-day and 200-day moving average...

Parmax Pharma Faces Intense Selling Pressure Amid Significant Price Declines

2025-03-04 10:53:30

Parmax Pharma Ltd is currently facing significant selling pressure, with the stock showing only sellers today. The company has experienced consecutive days of losses, with a notable decline of 9.98% in just one day, compared to a minimal drop of 0.20% in the Sensex. Over the past week, Parmax Pharma's performance has worsened by 10.63%, while the Sensex fell by 2.23%. In the last month, the stock has declined by 11.66%, significantly underperforming the Sensex, which decreased by 7.18%. The three-month performance reveals a stark drop of 21.97% for Parmax Pharma, against the Sensex's 9.90% decline. Year-to-date, the stock is down 13.15%, while the Sensex has fallen by 6.66%. Despite a strong one-year performance of 21.46%, Parmax Pharma's three-year performance shows a decline of 14.60%, contrasting sharply with the Sensex's growth of 34.24%. The stock's erratic trading pattern, with no trades on one da...

Parmax Pharma Faces Intensified Selling Pressure Amid Ongoing Price Declines

2025-03-03 10:25:03

Parmax Pharma Ltd is currently facing significant selling pressure, with today's trading session showing only sellers in the market. This trend marks a continuation of consecutive days of losses for the microcap pharmaceutical company. Over the past week, Parmax Pharma has declined by 2.04%, slightly outperforming the Sensex, which fell by 2.13%. However, the stock's performance over the past month shows a loss of 5.55%, closely trailing the Sensex's decline of 5.60%. In the last three months, Parmax Pharma has experienced a more pronounced drop of 11.06%, compared to the Sensex's 9.87% decline. Despite a strong yearly performance of 31.39% against the Sensex's -1.27%, the stock has struggled in the year-to-date, down 3.53% versus the Sensex's 6.75% loss. Over three years, Parmax Pharma has underperformed with a decline of 5.87%, while the Sensex has surged by 32.24%. Today's trading activity indicates e...

Parmax Pharma Reports Strong Sales Growth Amid Market Reevaluation in February 2025

2025-02-17 11:16:33

Parmax Pharma announced its financial results for the quarter ending December 2024, revealing net sales of Rs 15.56 crore, marking a year-on-year growth of 188.15%. This performance underscores the company's operational momentum, while a recent adjustment in its market score indicates a reassessment of its overall standing in the competitive pharmaceuticals sector.

View All News

Announcement

Closure of Trading Window

24-Mar-2025 | Source : BSE

Pursuant to SEBI (PIT) Regulations 2015 trading window for dealing in securities of the company for designated persons will remain closed from 1st April 2025 till 48 hours after declaration of financial results for the quarter ending on 31st March 2025.

Board Meeting Outcome for Outcome Of Board Meeting

14-Feb-2025 | Source : BSE

Pursuant to the provisions of Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the Board of Directors of the Company at its meeting held today i.e. November 14 2024 inter alia has considered and approved: 1. The Unaudited Financial Results of the Company for the quarter and half year ended on September 30 2024. The same has also been reviewed by the Audit Committee in its meeting held today. 2. B A Shah S R Mehta & Co. Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Financial Results for the quarter and half year ended on September 30 2024 and the Board has also taken on record their Limited Review Report on the said Results.

Financial Results For The Quarter Ended On 31St December 2024

14-Feb-2025 | Source : BSE

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations 2015 the board of directors of the company at its meeting held today i.e. 14th February 2025 inter alia considered and approved Unaudited financial results of the company for the quarter ended on 31 st December 2024 along with Limited Review report provided by statutory auditors of the company.